[#바이오스펙테이터](?q=%23%EB%B0%94%EC%9D%B4%EC%98%A4%EC%8A%A4%ED%8E%99%ED%85%8C%EC%9D%B4%ED%84%B0) [#전일](?q=%23%EC%A0%84%EC%9D%BC)(11/19, THU) [#전체기사](?q=%23%EC%A0%84%EC%B2%B4%EA%B8%B0%EC%82%AC)

 셀라스, 'WT1 암백신' 백혈병 3상 "사망위험 41%↓"
[https://www.biospectator.com/news/view/30448](https://www.biospectator.com/news/view/30448)

 로슈, SERD '첫 초기유방암 승인결정' 앞두고 “美시판허가”
[https://www.biospectator.com/news/view/30450](https://www.biospectator.com/news/view/30450)

 펩트론, '월1회 세마글루타이드' 국내 1상 "IND 승인"
[https://www.biospectator.com/news/view/30468](https://www.biospectator.com/news/view/30468)

 씨어스, 코스닥150 신규 편입…"주요 3개 지수 편입"
[https://www.biospectator.com/news/view/30469](https://www.biospectator.com/news/view/30469)

 온코닉, ‘GLP-1병용 근육보존' 비임상 결과 "구두발표" 
[https://www.biospectator.com/news/view/30441](https://www.biospectator.com/news/view/30441)

 퍼스트바이오, 'ISR 삼중작용제' 항암제 "KDDF 과제선정"
[https://www.biospectator.com/news/view/30465](https://www.biospectator.com/news/view/30465)

 GSK, 누발란트 'ALK 저해제' 폐암 2차 "美 가속승인"
[https://www.biospectator.com/news/view/30447](https://www.biospectator.com/news/view/30447)

 셀트리온, 亞서 주요 시밀러 제품군 "점유율 1위 지속" 
[https://www.biospectator.com/news/view/30467](https://www.biospectator.com/news/view/30467)

 화이자, 中스타나 '인비보 CAR-T 3종' 26억弗 사들여 
[https://www.biospectator.com/news/view/30462](https://www.biospectator.com/news/view/30462)

 대웅제약-티온랩, ‘월1회 GLP-1’ 국내 1상 "IND 승인"
[https://www.biospectator.com/news/view/30463](https://www.biospectator.com/news/view/30463)

 [인사]HLB그룹, 임원승진 인사
[https://www.biospectator.com/news/view/30470](https://www.biospectator.com/news/view/30470)

[#바이오스펙테이터](?q=%23%EB%B0%94%EC%9D%B4%EC%98%A4%EC%8A%A4%ED%8E%99%ED%85%8C%EC%9D%B4%ED%84%B0) [#전일](?q=%23%EC%A0%84%EC%9D%BC)(11/19, THU) [#전체기사](?q=%23%EC%A0%84%EC%B2%B4%EA%B8%B0%EC%82%AC)